D-pinitol

D-Pinitol: A Comprehensive Encyclopedic Reference

1. Identity, Chemistry, and Natural Sources

1.1 Chemical Identity and Nomenclature

D-pinitol is the 3-O-methyl ether of D-chiro-inositol, bearing the systematic IUPAC designation (1R,2S,3R,4S,5S,6S)-6-methoxycyclohexane-1,2,3,4,5-pentol. It is formally classified as a cyclitol and is nearly ubiquitous in the Leguminosae and Pinaceae families. Synonyms recorded in the chemical literature include (+)-pinitol, Pinit, Sennitol, and Matezitol. D-pinitol is the D-enantiomer of pinitol. It has a role as a geroprotector and a member of compatible osmolytes, and is functionally related to 1D-chiro-inositol, of which it is the 3-O-methyl ether.

The pharmacological interest in this compound has risen owing to its established multifunctional properties through a variety of signalling pathways, including anti-cancer activity through inhibition of TNF-α and suppression of the NF-κB pathway; insulinomimetic and metabolic regulatory activity in type 2 diabetes mellitus; and anti-aging effects via reduction of the insulin/IGF-1 signalling (IIS) pathway.

1.2 Natural Sources and Occurrence

D-Pinitol is a naturally occurring inositol that can be found in many plant species. It was first identified in the sugar pine (Pinus lambertiana), from which the name "pinitol" derives. D-pinitol has a wide range of plant sources, and was first found in the Pinaceae family of plants. Later, D-pinitol was also found in leguminous plants, where its content is quite abundant, greatly expanding the known plant sources.

D-Pinitol can be found in more than 20 plant sources, and its highest content is in carob pods (Ceratonia siliqua L.) at 5.5%. Carob has the highest content of D-Pinitol and has a wide range of medicinal and other properties. D-pinitol was determined in carob syrup samples in concentrations ranging 65.71 ± 4.60–77.72 ± 5.44 mg/g (mean: 68.58 ± 4.80 mg/g). It was determined in high concentrations in carob flesh samples, ranging 53.20 ± 3.72–54.58 ± 3.82 mg/g, while seed samples proved very poor in D-pinitol. Compared to other plants or legumes, carob appears to be the richest source of D-pinitol.

Other major botanical sources include soybeans (Glycine max) and Bougainvillea spectabilis. D-Pinitol is the most abundant sugar alcohol in many Leguminosae species, including Glycine max (soybean). It is a naturally occurring compound found in pine wood, alfalfa, and legumes, but is generally derived from soy or carob for manufacturing purposes. Additional documented sources include many plants, among them the ayurvedic remedies known as Talisa patra (Abies webbiana, A. pindrow), and the antidiabetic plant Bougainvillea spectabilis.

Although many synthetic and semi-synthetic methods have been reported for D-pinitol and its derivatives, through chemical and biochemical transformations, Ceratonia siliqua L. (carob), a Mediterranean tree, is the only raw material from which D-pinitol can be isolated in quantities sufficient for viable commercial exploitation.

1.3 Biosynthesis in Plants

D-pinitol is the most widely distributed inositol ether in plants. In angiosperms, D-pinitol has a relatively straightforward and short biosynthesis which proceeds via the Loewus pathway. The precursor to the biosynthesis pathway is glucose-6-phosphate, which is converted to D-ononitol (1-D-4-O-methyl-myo-inositol) via myo-inositol. Pinitol is thought to be synthesized in a two-step pathway involving the methylation of myo-inositol, followed by epimerization of the methylated intermediate.

D-pinitol plays an important role in plants as a physiological cellular modulator and as a chemical defense against unfavorable environmental conditions, such as water deficit and high levels of salinity. D-pinitol is the most commonly accumulated sugar alcohol in the Leguminosae family and has been observed to increase significantly in response to abiotic stress.

1.4 Common Forms and Preparations

D-pinitol is available commercially as a white crystalline powder extracted primarily from carob pods or soybean meal. It is sold as a stand-alone dietary supplement in capsule or tablet form and is also incorporated into combination metabolic and sports-nutrition formulations. Research-grade material has been used in both pure crystalline form and as a constituent of food-derived syrups (such as carob pod syrup) in pharmacokinetic studies. Carob (Ceratonia siliqua L.) is the only raw material from which D-pinitol can be isolated in commercially viable quantities.

---

2. Traditional and Historical Use

Plants rich in D-pinitol are being used in traditional medicine as empirical treatment for diabetes, inflammation, cancer, and infections. The traditions span multiple cultures and continents.

2.1 Ayurvedic Tradition (India)

D-pinitol can be found in and isolated from many plants, being the active component of ayurvedic remedies such as Talisa patra (Abies webbiana, A. pindrow). D-pinitol is an active principle of the antidiabetic plant Bougainvillea spectabilis, traditionally known for its insulin-like effects. Pinitol has a history of traditional medicinal use across geographical barriers, including China, Sri Lanka, and India.

2.2 Traditional Use via Carob (Mediterranean Basin)

Carob is one of the major food trees for peoples of the Mediterranean basin, but it has also been traditionally used for medicinal purposes. Carob contains many nutrients and active natural products, and D-Pinitol is clearly one of the most important of these. Mediterranean communities have long consumed carob pods and carob-derived syrups as food and as traditional remedies.

2.3 Traditional Use via Bougainvillea spectabilis

Bougainvillea spectabilis Willd. is a widely used herbal remedy with diverse cultivars traditionally used for diabetes treatment. In traditional systems across South Asia and Latin America, preparations from the leaves and bracts of this plant were used to manage blood sugar, and D-pinitol has been identified as a key active constituent underlying this ethnobotanical use.

2.4 Traditional Use via Pterocarpus marsupium and Legumes

D-Pinitol is found abundantly in the leaves and pods of certain legumes and in plants such as soybeans, carob, and especially the leaves of Pterocarpus marsupium (Indian Kino tree). It is a type of cyclitol that has long been recognized in traditional medicine for its therapeutic properties. In Ayurveda, the sap and extracts of these plants have been used for centuries to help manage blood sugar levels, reflecting an early understanding of D-pinitol's insulin-mimetic effects.

2.5 Traditional Use via Sutherlandia frutescens

Pinitol is a known antidiabetic agent isolated from Sutherlandia frutescens leaves, a plant used extensively in southern African traditional medicine as a treatment for a range of ailments including wasting conditions and metabolic disease.

---

3. Key Constituents, Chemistry, and Established Mechanisms of Action

3.1 Chemical Classification

Pinitol is a cyclitol, a cyclic polyol. It belongs to the broader inositol family, six stereoisomers of which are naturally occurring, though D-pinitol itself is a methyl-ether derivative rather than a free inositol. It has a role as a geroprotector and a member of compatible osmolytes. The molecule's structural relationship to D-chiro-inositol (DCI) is crucial to understanding its pharmacology: D-pinitol (3-O-methyl-D-chiro-inositol) is a methyl derivative of D-chiro-inositol.

3.2 Insulin-Sensitizing Mechanism

Published research reviews conclude that D-Pinitol has two mechanisms of action as an insulin regulator: insulin sensitizing and insulin mimetic.

As an insulin sensitizer, D-pinitol acts through the PI3K/Akt signalling cascade. Insulin enters the cell through an insulin receptor. As a result, tyrosine phosphorylation occurs on the insulin receptor substrate (IRS) protein. The resulting adduct activates phosphoinositide 3-kinase (PI3K), resulting in activation of phosphoinositide-dependent kinase-1,2 (PDK1/2). Protein kinase (AKT) gets phosphorylated by PDK1/2 and promotes glucose transporter 4 (GLUT4) translocation to the plasma membrane, facilitating glucose entry into cells.

The amelioration of insulin resistance in T2DM promoted by D-pinitol was found to occur through the PI3K/Akt pathway, similarly to other inositol phosphates.

As an insulin mimetic, the effectiveness of D-pinitol is related to the ability of this compound to stimulate the mobility of Glucose Transporter 4 (GLUT4), which, according to its sensitivity to insulin, plays an important role in the regulation of glucose transportation to the skeletal muscle and the adipose tissue. The PI3K/Akt signalling pathway is involved in this process through a protein phosphorylation cascade. Therefore, D-pinitol stimulates a reduction of plasma glucose levels under conditions of high glucose levels.

Pinitol (3-O-methyl-D-chiro-inositol) was identified in putative insulin mediator fractions that have hypoglycemic activity, and appears to mimic the effects of insulin by acting downstream in the insulin signalling pathway.

3.3 Anti-Inflammatory Mechanisms

Previous studies revealed that D-pinitol exhibits anti-inflammatory activity via suppression of the NF-κB pathway. In vitro evidence demonstrates that treatment with D-pinitol induces a reduction in pro-inflammatory factors such as NF-κB and cytokines such as TNF-α. In animal studies, D-pinitol at doses of 10, 20, and 40 mg/kg substantially decreased pro-inflammatory cytokines TNF, IL-6, and IL-1 levels in mice.

3.4 Antioxidant Mechanisms

Pre-treatment with pinitol (10 and 20 mg/kg) effectively protected against ischemia-reperfusion injury-induced hepatic damage, reflected by attenuation of elevated oxidative stress and pro-inflammatory cytokines. The compound's antioxidant effects are considered relevant to its hepatoprotective and renoprotective activities.

3.5 Mechanisms in Bone Metabolism

D-pinitol significantly restored the expression of osteogenic markers inhibited by TNF-α. D-pinitol, a naturally occurring inositol derivative found in legumes and soy-based foods, has shown various biological effects, including anti-inflammatory and insulin-sensitizing activities. Pinitol treatment significantly recovered depleted D-chiro-inositol (DCI) content and the decreased ratio of DCI to myo-inositol caused by diabetic osteoporosis. Results suggested that pinitol improved glucose metabolism and inhibited bone loss in diabetic osteoporosis mice via elevating the DCI levels in tissues.

3.6 Neuroprotective Mechanisms

D-pinitol has been investigated under the research designation NIC5-15 for Alzheimer's disease. NIC5-15 (D-pinitol) is a cyclic sugar alcohol which acts as an insulin sensitizer and is found in pine bark, soy, and other plants. In preclinical animal models, NIC5-15 reduces the production of Aβ1-42 by inhibiting notch-sparing γ-secretase.

More detailed mechanistic work reveals multiple parallel neuroprotective pathways. D-Pinitol inhibits the specifically pathogenic activation of tau-activating kinase CDK5, preventing the cleavage of its bound protein p35 into active p25, thus reducing tau hyperphosphorylation and microtubule destabilization. D-Pinitol, either as a single molecule or forming a pseudodisaccharide, also activates protein phosphatase 1A (PP2Cα), known to actively dephosphorylate tau. D-Pinitol is also able to activate IRS1 and decrease the activation of glycogen synthase protein kinase-3β (GSK-3β), which also promotes tau hyperphosphorylation. D-Pinitol is also able to reduce γ-secretase activity specifically in the amyloidogenic pathway of pathogenic amyloid β fragment formation, leaving intact the Notch pathway.

---

4. Scientific Evidence by Area of Use

4.1 Glucose Metabolism and Type 2 Diabetes Mellitus

Animal and In Vitro Evidence

D-pinitol, a compound isolated from Pinaceae and Leguminosae plants, has been reported to possess insulin-like properties. Although the hypoglycemic activity of D-pinitol was recognized in recent years, the molecular mechanism in the treatment of diabetes mellitus remained unclear. A model of type 2 diabetes mellitus with insulin resistance was established by feeding a high-fat diet and injecting streptozotocin (STZ) to Sprague-Dawley rats. D-pinitol was administered to the diabetic rats at two doses (30 and 60 mg/kg body weight per day). The level of fasting blood glucose was decreased 12.63% in the high-dosage group, and the ability of oral glucose tolerance was improved in D-pinitol-treated groups. Biochemical indices revealed that D-pinitol had a positive effect on hypoglycemic activity.

Treatment with 1 mM D-pinitol increased glucose uptake in vitro in L6 myotubes, and induced the GLUT4 translocation to the plasma membrane both in vitro and ex vivo. However, the insulin mimetic effect of D-pinitol was not as prominent as expected according to previous in vivo studies; such differences may be due to the variability between these models and the timing of administration of D-pinitol prior to glucose intake.

Human Clinical Evidence

An important randomized controlled trial by Kim et al. (2012) enrolled 66 patients with type 2 diabetes. A total of 66 patients with type 2 diabetes who had been taking oral hypoglycemic agents for at least 3 months were enrolled and randomized to receive pinitol (n = 33) or matching placebo (n = 33). All subjects took 1,200 mg pinitol or placebo and maintained their current oral hypoglycemic agents throughout the study. Mean HbA1c, fasting plasma glucose, and HOMA-IR were significantly lowered more in patients taking pinitol than in those given a placebo. Patients who had an HbA1c over 8.0% showed a greater reduction (p < 0.01) than those who had an HbA1c below 8.0% (p = 0.16). In the group of patients with a HOMA-IR over 2.5, there was a significant decrease in HbA1c compared to the group with a HOMA-IR below 2. Pinitol can mediate insulin action to improve glycemic control and insulin sensitivity in patients with type 2 diabetes mellitus, especially in patients with insulin resistance, the authors concluded.

An earlier study evaluated pinitol in poorly controlled type 2 diabetic patients. The effect of pinitol therapy was evaluated in type 2 diabetic patients who were poorly controlled with hypoglycemic drugs such as sulfonylurea, metformin and/or insulin. Twenty type 2 diabetic patients were enrolled. Fasting glucose, fasting c-peptide, total cholesterol, triglyceride, and HDL- and LDL-cholesterol were checked before and after a 12-week pinitol treatment (20 mg kg⁻¹ day⁻¹). All subjects continued their current medications during the study. Adipocytokines such as adiponectin, leptin, free fatty acids, and CRP were also checked before and after pinitol treatment. After pinitol treatment, fasting glucose, post-prandial glucose levels, and hemoglobin A1c were significantly decreased (p < 0.05).

In contrast, a study in older humans demonstrated limitations. One group reported that oral supplementation of obese patients who had either type 2 diabetes mellitus or impaired glucose tolerance with 20 mg pinitol kg⁻¹ day⁻¹ for 4 weeks increased plasma pinitol concentration 48-fold. However, the study at the University of Arkansas for Medical Sciences found that pinitol supplementation did not affect insulin-mediated glucose metabolism and muscle insulin receptor content and phosphorylation in older humans, suggesting that responses may be population-dependent.

Evidence Assessment: Human evidence for glycemic effects is preliminary and derives from small studies (the largest RCT had only 66 participants). Results are directionally positive in populations with established insulin resistance and poor glycemic control, but the evidence base is insufficient to support definitive clinical conclusions. Several trials have been additive to existing oral hypoglycemic agents rather than testing D-pinitol as monotherapy.

4.2 Non-Alcoholic Fatty Liver Disease (NAFLD)

Liver histopathology showed diminished lipid accumulation in pinitol-treated hamsters, whereas the untreated group developed a fatty liver with significantly larger adipocytes. Pinitol also normalized liver ultrastructure changes caused by streptozotocin-induced diabetes in rats, which caused periportal fibrosis, hepatocyte and blood vessels distortion, microvesicular vacuolization, lipid accumulation, and mitochondria and glycogen reduction compared to untreated controls.

A key human RCT provides clinical data. In a 12-week, randomized, double-blind, placebo-controlled study, administration of pinitol (500 mg/day) in subjects with NAFLD showed inhibition of elevated AST (aspartate transaminase), ALT (alanine aminotransferase), and oxidative stress levels, demonstrating its hepatoprotective potential. The pinitol group showed significantly lower levels in liver fat content, plasma liver enzymes, fasting/postprandial urinary malondialdehyde levels, and postprandial triglyceride concentrations, but significantly higher glutathione peroxidase levels compared with the placebo group. Metabolomic analysis identified 27 differential metabolites involved in glycine/serine/threonine metabolism, alanine/aspartate/glutamate metabolism, and D-glutamine/D-glutamate metabolism, and fatty acid synthesis, implicating the role of pinitol in glutathione-related lipid and energy metabolism. These results suggest that pinitol may exert modulatory effects upon energy and metabolic pathways by reducing oxidative stress and fatty acid accumulation, leading to hepatoprotective benefits in NAFLD subjects.

However, a subsequent trial showed more nuanced results. A double-blind, placebo-controlled, randomized clinical trial was performed to evaluate the effects of two different doses of pinitol in 90 patients with NAFLD who were not taking medications and dietary supplements. After 12 weeks of treatment, no significant between-group differences in liver fat reduction were observed. However, there was a significant reduction in liver fat within one of the dosing groups.

Evidence Assessment: The NAFLD evidence base includes one positive RCT showing effects on liver enzymes and oxidative stress markers at 500 mg/day over 12 weeks, and one larger RCT (n = 90) without significant between-group differences in liver fat. The strongest clinical signal for D-pinitol appears to reside in this area, but the results are mixed and evidence remains preliminary.

4.3 Anti-Inflammatory Effects

D-pinitol exhibits anti-inflammatory activity via suppression of the NF-κB pathway. D-pinitol is a naturally occurring inositol with diverse biological activities including antioxidant, antimicrobial, and anticancer activities. Anti-inflammatory effect of D-pinitol has been evaluated in a chick model, and in silico studies were performed to evaluate molecular interactions with cyclooxygenase-2 (COX-2). The tested groups received D-pinitol (12.5, 25, and 50 mg/kg) and the standard drugs celecoxib and ketoprofen (42 mg/kg) via oral gavage prior to formalin injection. The number of licks was counted for the first 10 min, and paw edema diameter was measured at 60, 90, and 120 min. The D-pinitol groups significantly (p < 0.05) reduced the number of paw licks and paw edema diameters compared to the negative control. When D-pinitol was combined with celecoxib, it reduced inflammatory parameters more effectively than the individual groups.

Evidence Assessment: Anti-inflammatory evidence for D-pinitol is predominantly preclinical (animal models, in vitro cell culture, and in silico molecular docking). There are no dedicated human randomized controlled trials evaluating anti-inflammatory endpoints as primary outcomes. The mechanistic evidence—suppression of NF-κB, COX-2 inhibition, and reduction of TNF-α, IL-6, and IL-1—is consistent across multiple preclinical models, but translation to humans remains unproven in dedicated trials.

4.4 Anticancer Research

The status of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-2, IL-6, and tumor markers, lipid profile, and hormones was significantly declined upon D-pinitol administration in a rat breast carcinogenesis model. Mechanistically, D-pinitol promotes apoptosis in MCF-7 breast cancer cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-κB. There is evidence to support the role of NF-κB in the protection against programmed cell death. Inhibition of NF-κB/Rel proteins induces apoptosis, whereas overexpression of c-Rel protein makes cells resistant to apoptosis. Several studies have shown the absence or inhibition of NF-κB subunits in cultured cells resulting in potentiation of apoptosis in response to TNF-α, ionizing radiation and anticancer agents.

Evidence Assessment: Anticancer evidence for D-pinitol is entirely preclinical, based on cell-line studies (in vitro) and rodent carcinogenesis models (in vivo). No human clinical trials evaluating D-pinitol as an anticancer agent have been reported. This area should be characterized as hypothesis-generating only.

4.5 Bone Metabolism and Osteoporosis

Diabetic osteoporosis (DO) has been increasingly recognized as an important complication of diabetes. D-pinitol, a natural compound found in various legumes, is known for its anti-diabetic function, but its effect on DO had not been investigated. Two doses of pinitol (50 and 100 mg/kg body weight per day) were administered orally to an experimentally induced DO mouse model for 5 weeks. The results indicated that pinitol suppressed fasting blood glucose levels and tended to enhance impaired pancreatic function. Pinitol also suppressed serum bone turnover biomarkers, and improved dry femur weight, cancellous bone rate, and bone mineral content in the DO mice.

In a 2026 cell-based study, D-pinitol was investigated for its ability to alleviate TNF-α-induced suppression of osteogenic gene expression in MC3T3-E1 pre-osteoblasts. D-pinitol significantly restored the expression of osteogenic markers inhibited by TNF-α.

Evidence Assessment: Bone-related evidence is preclinical only (rodent models and cell culture). No human clinical trials addressing bone density or fracture outcomes have been published. The mechanistic rationale is reasonable but requires validation in human studies.

4.6 Creatine Retention and Athletic Performance

An exploratory area of research involves D-pinitol's potential to augment whole-body creatine retention. Greenwood, Kreider, Almada, and Earnest (2001) published findings that D-pinitol augments whole-body creatine retention in men, in the Journal of Exercise Physiology Online, Volume 4(4), pages 41–47. The proposed mechanism relates to pinitol's insulin-mimetic properties, as insulin is known to promote creatine uptake in muscle tissue via insulin-stimulated glucose transport pathways.

Evidence Assessment: Evidence in this area consists of a single small published study. It has not been independently replicated at sufficient scale and should be regarded as preliminary.

4.7 Neuroprotection and Alzheimer's Disease

D-pinitol has attracted growing scientific interest in the context of neurodegenerative disease, particularly Alzheimer's disease (AD). A critical narrative review published in 2026 examined interventional trials for nine prominent dietary bioactives relevant to AD, including NIC5-15 (D-pinitol). NIC5-15 (D-pinitol) acts as an insulin sensitizer. In preclinical animal models, NIC5-15 reduces the production of Aβ1-42 by inhibiting notch-sparing γ-secretase, a mechanism considered advantageous over classical γ-secretase inhibitors because it does not impair Notch signalling.

Multiple mechanistic pathways have been identified in preclinical research: D-Pinitol inhibits the specifically pathogenic activation of tau-activating kinase CDK5, preventing the cleavage of p35 into active p25, thus reducing tau hyperphosphorylation and microtubule destabilization. D-Pinitol also activates protein phosphatase 1A (PP2Cα), known to actively dephosphorylate tau. D-Pinitol activates IRS1 and decreases the activation of GSK-3β, which also promotes tau hyperphosphorylation. D-Pinitol reduces γ-secretase activity specifically in the amyloidogenic pathway of pathogenic amyloid β fragment formation.

Chronic administration of isoproterenol caused neurotoxicity, cognitive dysfunction, and histopathological changes in the brain evidenced by increase in GFAP, oxidative stress (via SOD, CAT, TBARS, and GSH), neuroinflammation (NF-κB, TNF-α, IL-6, and IL-10), and decrease in AchE and BDNF. D-pinitol has been assessed in these models of neuroinflammation and oxidative stress.

Evidence Assessment: Neuroprotective evidence is currently preclinical and mechanistic. No completed large-scale human RCTs assessing D-pinitol for cognitive decline or Alzheimer's disease have been published. This area is scientifically promising but requires substantial further investigation before clinical conclusions can be drawn.

4.8 Hepatoprotection

The hepatoprotective effect of pinitol against D-galactosamine-induced, high-fat diet-induced, and streptozotocin-induced hepatotoxicities has been well established in animal models. D-pinitol, a cyclic polyol, exhibits hepatoprotective efficacy. In a rat model of hepatic ischemia-reperfusion injury, male Sprague-Dawley rats were pre-treated orally with either vehicle or D-pinitol (5, 10, and 20 mg/kg) for 21 days, followed by 60 min of partial hepatic ischemia and 24 h of reperfusion. Pre-treatment with pinitol (10 and 20 mg/kg) effectively (p < 0.05) protected against IRI-induced hepatic damage reflected by attenuation of elevated oxidative stress and pro-inflammatory cytokines.

The antidiabetic effect of pinitol was mediated by a significant diminution in the generation of reactive oxygen species (ROS) in type 2 diabetes mellitus patients during a 12-week, double-blind, randomized trial.

4.9 Pharmacokinetics in Humans

A dedicated pharmacokinetic study in healthy human volunteers provides important data on absorption. The study characterized the oral pharmacokinetics of D-Pinitol, a natural insulin mimetic inositol, in human healthy volunteers (14 males and 11 females). D-Pinitol absorption was studied in (a) subjects receiving a single oral dose of 15 mg/kg (n = 10), or (b) 5 mg/kg pure D-Pinitol (n = 6), and (c) subjects receiving D-Pinitol as part of carbohydrate-containing carob pods-derived syrup with a 3.2% D-Pinitol (dose of 1600 mg/subject, n = 9).

Plasma concentration of D-Pinitol was measured and pharmacokinetic parameters obtained. The data indicate that when given alone, the oral absorption of D-Pinitol is dose-dependent and of extended duration, with a Tmax reached after almost 4 hours, and a half-life greater than 5 hours.

---

5. Body Systems and Health Areas

D-pinitol has been pharmacologically evaluated for its potent antioxidant, anti-diabetic, anti-inflammatory, anti-cancer, hepatoprotective, cardioprotective, renoprotective, neuroprotective, immunosuppressive, and anti-osteoporotic efficacies. The body systems involved include:

• Endocrine and metabolic system: Insulin signalling, glucose homeostasis, and glycemic control in type 2 diabetes.
• Musculoskeletal system: Skeletal muscle glucose uptake via GLUT4 translocation; bone density and osteoblast function.
• Hepatic system: Protection against oxidative and inflammatory liver injury; reduction of liver fat and liver enzymes in NAFLD.
• Central nervous system: Neuroprotection against tau hyperphosphorylation, amyloid-β production, and neuroinflammation in Alzheimer's disease models.
• Cardiovascular system: Preclinical evidence suggests cardioprotective properties, possibly related to antioxidant and lipid-lowering effects.
• Renal system: Renoprotective activity in models of cisplatin-induced and cyclosporine-induced nephrotoxicity.
• Immune system: Suppression of NF-κB and pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β.
• Skeletal system: Anti-osteoporotic effects via modulation of p38/JNK and NF-κB pathways and restoration of D-chiro-inositol levels in bone marrow.

---

6. Dosage Forms and Reported Dosages

The following dosages reflect those reported in specific published studies; they are not recommendations:

• In a 66-patient RCT of type 2 diabetes, all subjects took 1,200 mg pinitol (or matching placebo) per day while maintaining their oral hypoglycemic agents.
• In a 20-patient study of poorly controlled type 2 diabetics, the dose was 20 mg kg⁻¹ day⁻¹ for 12 weeks.
• In a 12-week, randomized, double-blind, placebo-controlled study in NAFLD subjects, pinitol was administered at 500 mg/day.
• In a pharmacokinetic study in 25 healthy volunteers, single oral doses of 15 mg/kg (n = 10) and 5 mg/kg (n = 6) pure D-pinitol were used, along with a carob syrup preparation delivering 1,600 mg/subject (n = 9).
• In a rodent T2DM model, D-pinitol was administered at two doses: 30 and 60 mg/kg body weight/day.
• In a diabetic osteoporosis mouse model, doses of 50 and 100 mg/kg body weight/day were administered orally for 5 weeks.
• In a hepatic ischemia-reperfusion injury rat model, D-pinitol was administered at 5, 10, and 20 mg/kg for 21 days.
• In a chick anti-inflammatory model, D-pinitol was tested at 12.5, 25, and 50 mg/kg via oral gavage.
• A dosage of up to 150 mg/kg body weight of D-pinitol was well tolerated in animal models and 1,200 mg/day in clinical studies.

The typical supplemental range used in available studies is 300–600 mg/day, usually with meals; some studies used single doses of approximately 15 mg/kg.

---

7. Safety Considerations and Interactions

7.1 General Tolerability

A dosage of up to 150 mg/kg body weight of D-pinitol was well tolerated in animal models, and 1,200 mg/day in case of clinical studies. Studies did not report any substantial toxic effects of D-pinitol.

7.2 Potential Interaction with Antidiabetic Medications

Because D-pinitol exerts demonstrated insulin-mimetic and insulin-sensitizing effects, its co-administration with glucose-lowering medications is a substantiated pharmacodynamic concern. In the studied diabetic patient populations, pinitol was evaluated as an add-on to patients already taking sulfonylurea, metformin, and/or insulin, and all subjects continued their current medications during the study. The additive glucose-lowering effects observed in these trials indicate that careful monitoring is warranted when combining D-pinitol with prescribed antidiabetic drugs.

7.3 Sex Differences in Pharmacokinetics

In the pharmacokinetic study combining male and female volunteers at doses of 15 and 5 mg/kg of D-pinitol, there were statistically significant differences between males and females (p < 0.05, 2-way ANOVA). The clinical significance of these sex-based pharmacokinetic differences is not yet fully characterized.

7.4 Metabolic Context: Relationship to D-Chiro-Inositol and Myo-Inositol

D-pinitol's structural relationship to D-chiro-inositol (DCI) is relevant to safety in specific populations. Some evidence suggests that D-chiro-inositol can directly regulate steroidogenic enzyme genes in human granulosa cells, reducing the expression of aromatase and cytochrome P450 side-chain cleavage genes, and increases testosterone levels in theca cells from PCOS women. These data suggest caution in treating PCOS women with high doses of D-chiro-inositol-related compounds. Given that D-pinitol is a precursor that can be demethylated to DCI in vivo, analogous caution is potentially warranted for D-pinitol in PCOS, though direct evidence specific to D-pinitol in this context is limited.

7.5 Renal Metabolism and Excretion

Available pharmacokinetic data in humans confirm oral bioavailability with a prolonged absorption phase. When given alone, the oral absorption of D-Pinitol is dose-dependent and of extended duration, with a Tmax reached after almost 4 hours, and a half-life greater than 5 hours. Urinary excretion of pinitol was tracked in the NAFLD RCT as part of metabolomic analysis, confirming renal clearance as a primary elimination route.

7.6 Insufficient Data Populations

No clinical data are available on the safety of D-pinitol supplementation in pregnant or breastfeeding individuals. No studies have specifically addressed safety in pediatric populations or in individuals with severe renal or hepatic impairment. These gaps mean that no evidence-based safety characterization can be made for these groups.

7.7 General Evidence Gaps

D-Pinitol has been reported in dozens of scientific publications and its very diverse medicinal properties are still being studied. Presently, more than thirty medicinal activities of D-Pinitol have been reported. Despite this breadth of research, the majority of studies are preclinical. Available comprehensive reviews validate the plausible pharmacological effects of D-pinitol using various in vivo and in vitro studies, but large-scale, long-term human randomized controlled trials across all proposed indications remain absent from the literature.

---

References

• Azab A. D-Pinitol—Active Natural Product from Carob with Notable Insulin Regulation. Nutrients. 2022;14(7):1453. PMC9003036.
• León-González AJ, Sánchez-Hidalgo M, González-Mauraza NH, Martin-Cordero C. d-Pinitol: a cyclitol with versatile biological and pharmacological activities. Phytochemistry Reviews. 2020;20:649–670.
• Pandi A et al. Pharmacological effects of D-Pinitol – A comprehensive review. Journal of Food Biochemistry. 2022;46(6):e14282. PubMed PMID: 35735162.
• Murugesan M et al. Effects of d-pinitol on diabetes mellitus: an updated review. Bulletin of the National Research Centre. 2022;46:115.
• Castilla-Ortega E et al. Pharmacokinetics and Endocrine Effects of an Oral Dose of D-Pinitol in Human Fasting Healthy Volunteers. Nutrients. 2022;14(19):4094. PMC9572189.
• Kim JI et al. Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice. 2007;77(2):P188.
• Kim HJ, Park KS, Lee SK et al. Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. Annals of Nutrition and Metabolism. 2012;60(1):1–5. PubMed PMID: 22179130.
• Gao Y et al. Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2 Diabetes Mellitus Rats. Journal of Agricultural and Food Chemistry. 2015;63(26):6019–6026. PubMed PMID: 26063468.
• Dang NT, Mukai R, Yoshida K, Ashida H. d-Pinitol and myo-Inositol Stimulate Translocation of Glucose Transporter 4 in Skeletal Muscle of C57BL/6 Mice. Bioscience, Biotechnology, and Biochemistry. 2010;74(5):1062–1067.
• Kim M et al. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Nutritional Biochemistry. 2019;67:140–149.
• Petäjä EM, Yki-Järvinen H. Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients. 2020;12(11):3379. PMC7694137.
• Velu P et al. d-Pinitol protects against endoplasmic reticulum stress and apoptosis in hepatic ischemia-reperfusion injury via modulation of AFT4-CHOP/GRP78 and caspase-3 signaling pathways. Pharmacological Reports. 2021;73:1546–1558. PMC8287360.
• Taher MA et al. Anti-inflammatory activity of d-pinitol possibly through inhibiting COX-2 enzyme: in vivo and in silico studies. Frontiers in Chemistry. 2024;12:1366844. PMC11058972.
• Vinothkumar R et al. D-pinitol mitigates tumor growth by modulating interleukins and hormones and induces apoptosis in rat breast carcinogenesis through inhibition of NF-κB. Molecular and Cellular Biochemistry. 2015;405(1–2):89–101. PubMed PMID: 25827943.
• Liu X, Koyama T. D-Pinitol Improved Glucose Metabolism and Inhibited Bone Loss in Mice with Diabetic Osteoporosis. Molecules. 2023;28(9):3870. PMC10180393.
• Kim H et al. d-Pinitol Rescues Osteoblast Differentiation From Tumor Necrosis Factor-Alpha-Mediated Suppression via β-Galactoside α-2,6-Sialyltransferase 1 Induction. Cell Biochemistry and Function. 2026;44:e70213.
• Antón M et al. Novel insights into D-Pinitol based therapies: a link between tau hyperphosphorylation and insulin resistance. Frontiers in Molecular Neuroscience. 2023. PMC10503604.
• Rajamanikandan R et al. D-Pinitol improves cognitive dysfunction and neuronal damage induced by isoproterenol via modulation of NF-κB/BDNF/GFAP signaling in Swiss albino mice. Frontiers in Pharmacology. 2024. PMC10849198.
• Ibrahim AM et al. D-Pinitol Content and Antioxidant and Antidiabetic Activities of Five Bougainvillea spectabilis Willd. Cultivars. Pharmaceuticals. 2023;16(7):1008.
• Muñoz-Cuervo I et al. D-pinitol, a highly valuable product from carob pods: Health-promoting effects and metabolic pathways. AIMS Agriculture and Food. 2018;3(1):41–63.
• Greenwood M, Kreider RB, Almada AL, Earnest CP. D-Pinitol augments whole body creatine retention in man. Journal of Exercise Physiology Online. 2001;4(4):41–47.
• Monastra G et al. PCOS and Inositols: Controversial Results and Necessary Clarifications. Basic Differences Between D-Chiro and Myo-Inositol. Frontiers in Endocrinology. 2021;12:653984. PMC8056130.
• Pinitol. Wikipedia (consulted June 2026; used only for first-identification reference).
• Rodà D et al. Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. Nutrients. 2026;18(6):907.